This policy outlines how the College complies with UK Data Protection legislation.
Delayed access to care for children during COVID-19: our role as paediatricians - position statement
Evidence is emerging that children and families are not accessing medical advice and review as soon as is needed. In this position statement, published 3 April 2020, we outline our role as paediatricians to help ensure children get the right care at the right time and right place.
The use of unlicensed medicines or licensed medicines for unlicensed applications in paediatric practice
This statement, originally produced in 2000, was updated in 2013 by the Joint Standing Committee on Medicines, a committee of the Royal College of Paediatrics and Child Health and the Neonatal and Paediatric Pharmacists Group. The update reflects changes in European (including UK) law that aim to fa...
The aim of this evidence-based statement is to summarise the current knowledge about delayed prescriptions (also called backup prescriptions) for antibiotics and to highlight the special issues that must be taken into account when considering the need for a delayed prescription in infants and childr...
The Neonatal and Paediatric Pharmacists Group (NPPG) and the Royal College of Paediatrics and Child Health (RCPCH) strongly recommend that when children require unlicensed liquid medications, they should receive the RCPCH and NPPG recommended strength, where one exists. There are currently 12 such r...